BioCentury | Sep 7, 2015
Company News

Lupin, Temmler deal

...Lupin will acquire a portfolio of 13 products from Temmler. The portfolio includes products to treat...
...HD) and warts. The companies did not respond to inquiries. Lupin Ltd. (NSE:LUPIN;BSE:500257), Mumbai, India Temmler Pharma GmbH & Co. KG...
BioCentury | Sep 17, 2009
Distillery Therapeutics

Indication: Neurology

...VMAT2; SLC18A2) from Cambridge Laboratories Ltd., Biovail Corp., Chiesi Farmaceutici S.p.A., EUSA Pharma Inc. and Temmler Pharma GmbH & Co. KG...
BioCentury | Oct 22, 2007
Clinical News

Xenazine tetrabenazine regulatory update

...from Cambridge and markets the compound as Nitoman in Canada to treat hyperkinetic movement disorders. Temmler Pharma GmbH & Co. KG...
BioCentury | Aug 20, 2007
Clinical News

Xenazina tetrabenazine regulatory update

...Xenazine , in Australia as Tetrabenazine, and as Nitoman in Canada and certain European countries. Temmler Pharma GmbH & Co. KG...
BioCentury | May 7, 2007
Clinical News

Nitoman tetrabenazine: Extension study data

...U.K. EUSA Pharma Inc. , King of Prussia, Penn. Prestwick Pharmaceuticals Inc. , Washington, D.C. Temmler Pharma GmbH & Co. KG...
BioCentury | Mar 19, 2007
Company News

Cambridge Laboratories, Temmler sales and marketing update

...the selective inhibitor of vesicular monoamine transporter (VMAT2) in South Africa, New Zealand and Australia. Temmler...
...chorea associated with Huntington's disease in February. Cambridge Laboratories Ltd. , Tyne & Wear, U.K. Temmler Pharma GmbH & Co. KG...
BioCentury | Feb 19, 2007
Clinical News

Nitoman tetrabenazine regulatory update

...transporter (VMAT2) as Xenazine in South Africa and New Zealand and as Tetrabenazine in Australia. Temmler...
...Tyne & Wear, U.K. OPi S.A. , Lyon, France Prestwick Pharmaceuticals Inc. , Washington, D.C. Temmler Pharma GmbH & Co. KG...
BioCentury | Jan 1, 2007
Company News

Astellas, Temmler deal

...manufacturing facilities in Germany, Ireland and Italy to contract manufacturer Temmler for an undisclosed sum. Temmler...
...Astellas with the products produced at the three plants. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Temmler Pharma GmbH & Co. KG...
BioCentury | May 29, 2006
Company News

Cambridge Laboratories, Temmler Pharma sales and marketing update

...Cambridge Labs granted Temmler exclusive marketing and distribution rights to Nitoman in Germany and Austria. The...
...dyskinesia and chorea associated with Huntington's disease. Cambridge Laboratories Ltd. , Tyne & Wear, U.K. Temmler...
Items per page:
1 - 9 of 9
BioCentury | Sep 7, 2015
Company News

Lupin, Temmler deal

...Lupin will acquire a portfolio of 13 products from Temmler. The portfolio includes products to treat...
...HD) and warts. The companies did not respond to inquiries. Lupin Ltd. (NSE:LUPIN;BSE:500257), Mumbai, India Temmler Pharma GmbH & Co. KG...
BioCentury | Sep 17, 2009
Distillery Therapeutics

Indication: Neurology

...VMAT2; SLC18A2) from Cambridge Laboratories Ltd., Biovail Corp., Chiesi Farmaceutici S.p.A., EUSA Pharma Inc. and Temmler Pharma GmbH & Co. KG...
BioCentury | Oct 22, 2007
Clinical News

Xenazine tetrabenazine regulatory update

...from Cambridge and markets the compound as Nitoman in Canada to treat hyperkinetic movement disorders. Temmler Pharma GmbH & Co. KG...
BioCentury | Aug 20, 2007
Clinical News

Xenazina tetrabenazine regulatory update

...Xenazine , in Australia as Tetrabenazine, and as Nitoman in Canada and certain European countries. Temmler Pharma GmbH & Co. KG...
BioCentury | May 7, 2007
Clinical News

Nitoman tetrabenazine: Extension study data

...U.K. EUSA Pharma Inc. , King of Prussia, Penn. Prestwick Pharmaceuticals Inc. , Washington, D.C. Temmler Pharma GmbH & Co. KG...
BioCentury | Mar 19, 2007
Company News

Cambridge Laboratories, Temmler sales and marketing update

...the selective inhibitor of vesicular monoamine transporter (VMAT2) in South Africa, New Zealand and Australia. Temmler...
...chorea associated with Huntington's disease in February. Cambridge Laboratories Ltd. , Tyne & Wear, U.K. Temmler Pharma GmbH & Co. KG...
BioCentury | Feb 19, 2007
Clinical News

Nitoman tetrabenazine regulatory update

...transporter (VMAT2) as Xenazine in South Africa and New Zealand and as Tetrabenazine in Australia. Temmler...
...Tyne & Wear, U.K. OPi S.A. , Lyon, France Prestwick Pharmaceuticals Inc. , Washington, D.C. Temmler Pharma GmbH & Co. KG...
BioCentury | Jan 1, 2007
Company News

Astellas, Temmler deal

...manufacturing facilities in Germany, Ireland and Italy to contract manufacturer Temmler for an undisclosed sum. Temmler...
...Astellas with the products produced at the three plants. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Temmler Pharma GmbH & Co. KG...
BioCentury | May 29, 2006
Company News

Cambridge Laboratories, Temmler Pharma sales and marketing update

...Cambridge Labs granted Temmler exclusive marketing and distribution rights to Nitoman in Germany and Austria. The...
...dyskinesia and chorea associated with Huntington's disease. Cambridge Laboratories Ltd. , Tyne & Wear, U.K. Temmler...
Items per page:
1 - 9 of 9